Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329497 | 0.85 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C19TDP1LMNA | |
| SCHEMBL2328729 | 0.85 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C19TDP1LMNA | |
| SCHEMBL2106482 | 0.80 | MEN1 (0.41) | CYP1A2CYP2C19TDP1LMNAMEN1 | |
| SCHEMBL2106651 | 0.80 | MEN1 (0.41) | CYP1A2CYP2C19TDP1LMNAMEN1 | |
| SCHEMBL2330442 | 0.77 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C19TDP1MEN1 | |
| SCHEMBL2332116 | 0.75 | MEN1 (0.43) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2329485 | 0.75 | MEN1 (0.43) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2332522 | 0.74 | KMT2A (0.42) | CYP1A2CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL2106773 | 0.72 | MEN1 (0.39) | CYP1A2CYP2C19TDP1MEN1KMT2A | |
| SCHEMBL3292156 | 0.70 | TAS1R3 (0.46) | CYP1A2CYP3A4CYP2C19LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158650-B2 | Substituted phenylmethyl bicyclocarboxyamide compounds | PFIZER INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER INC. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | TRPV1, P2RY1, TRPV2 | CYP1A2 1772/4885CYP3A4 2344/4885CYP2C19 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.